Poster Presentations

Breast cancer genetics

P01 Contribution of germline mutations in lysosomal storage disease-related genes contributes to breast cancer development
Han-Byoel Lee, South Korea
P02 Multifocality in BRCA-associated breast cancer: A cross-sectional analysis
Stuart Mcintosh, UK

Breast cancer screening

P03 Women informed to screen depending on measures of risk (WISDOM): A personalized breast cancer screening in a population based study
Irene Acerbi, USA
P04 Has the transition to digital mammography in breast cancer screening resulted in real benefits?
Rachel Farber, Australia
P05 Barriers and lessons learned after implementing coverage with evidence progression with private payers in a national, precision medicine breast screening trial
Yash Huilgol, USA

Breast imaging

P06 Correlation of breast background parenchymal enhancement on MRI with morphophysiological parameters of breast and breast lesions
Zehra Hilal Adibelli, Turkey
P07 Pure fibrocystic change diagnosed at MRI-guided vacuum-assisted breast biopsy: Imaging features and follow-up outcomes
Shu-Tian Chen, USA
P08 A multi-center open-label parallel phase-2 clinical trial to evaluate the efficacy and safety of LuminoMarktm for localization in patients with non-palpable breast lesions
Seung Ki Kim, South Korea
P09 Factors associated with MRI detection of occult lesions in newly diagnosed breast cancer
Julie Lang, USA
P10 3D automatic density analysis device might be better for accurate breast density in Japanese women with breast cancer
Misaki Matsuyanagi, Japan
P11 Magnetic resonance imaging features of pure sclerosing adenosis in the breast undergoing vacuum assisted breast core biopsy
Satoko Okamoto, Japan
P12 Radial sclerosing lesions of the breast. A single-institution experience and literature review
Nikolaos Salemis, Greece
P13 Unique characteristics of the breast density (cancer, benign disease, screening) in Japanese women are clarified by using VolparaTM
Terumasa Sawada, Japan
P14 Utility of contralateral breast ultrasound in diagnosing synchronous breast cancer in newly diagnosed cancer patients
Ying Ching Tan, Singapore

Breast reconstruction

P15 Outcomes and complications of immediate and delayed breast reconstruction
Marwa Badawi, UK
P16 What should be used for lower pole coverage in immediate two-stage expander/implant breast reconstruction? A feasibility study
Negin Sedaghat, Australia


P17 Patient-centered initiatives to enhance recruitment to the COMET study
Donna Pinto, USA

Endocrine resistance

P18 Response rate by geographic region in patients with hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer from the SOLAR-1 trial
Ingrid Mayer, USA

Her2 positive breast cancer

P19 Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage ER+/HER2− breast cancer
Javier Cortes, Spain
P20 Fluorescence in situ hybridization analysis of HER2 3+ breast cancer patients with neoadjuvant chemotherapy using pertuzumab and trastuzumab
Choi Jin Hyuk, South Korea

Locoregional therapy

P21 A case of metaplastic breast carcinoma presenting as a bleeding breast mass
Ma Corazon Cabanilla-Manuntag, Philippines
P22 Factors associated with false negative rate of sentinel lymph node biopsy in breast cancer patients
Joyce Hazel Chua, Philippines
P23 Can we avoid axillary lymph node dissection (ALND) in patients with 1-2 positive sentinel/low axillary lymph nodes (SLN/LAS+) in the Indian setting?
Asha Reddy, India
P24 Breast carcinoma with medullary features. A clinicopathologic study
Nikolaos Salemis, Greece
P25 Adenoid cystic carcinoma of the breast
Nikolaos Salemis, Greece
P26 Examination of the appropriate treatment for elderly breast cancer patients over 80
Shinichi Sekine, Japan
P27 Does metastatic inflammatory breast cancer have a worse prognosis after surgery?
Yoko Takahashi, Japan

Molecular assays

P28 How patient advocates and researchers work together in PRECISION* to identify low-risk ductal carcinoma in situ (DCIS) that may not need aggressive treatment
Deborah Collyar, USA
P29 Somatic mutation in breast cancer through next generation sequencing: A single institution experience
Choi Jin Hyuk, South Korea

Neoadjuvant therapy

P30 A randomized controlled trial to compare the efficacy of hyperbaric oxygen along with neoadjuvant chemotherapy with neoadjuvant chemotherapy alone for carcinoma breast
Rijuta Aphale, India
P31 A call to change world guidelines: Medical therapy 1st
Maria Antonia Coccia-Portugal, South Africa
P32 Risk of ipsilateral breast tumor recurrence in breast conserving surgery after neoadjuvant therapy
Se Young Kim, South Korea
P33 Radiologic complete response after neoadjuvant chemotherapy in advanced breast cancer can predict survival outcome, but not pathologic complete response
Jinsun Woo, South Korea

Oncoplastic surgery

P34 Periaeolar round block technique of breast conserving surgery: A single institution experience
Choi Jin Hyuk, South Korea


P35 Elevated levels of serum tumor maker p53 is a prognostic paramator and a monitoring biomaker for patients who had undergone surgical resection in breast cancer
Mie Arai, Japan
P36 Development and pilot of a personalized, online prevention decision aid for breast cancer risk reduction in the WISDOM study
Yash Huilgol, USA


P37 Comparison of ESTRO and RTOG contouring guidelines for target volume delineation in early stage breast cancers
Tony Mathew, Australia
P38 A dosimetric comparison of tangent FIF, VMAT and hybrid-VMAT for chest wall radiation therapy with AeroForm tissue
Charlene Tan, USA
P39 A practical formula to guide partial inflation of contralateral tissue expanders for optimal post-mastectomy radiation
Charlene Tan, USA
P40 Preliminary results of hypofractionated post-mastectomy radiotherapy (PMRT-HF): Dosimetry, loco-regional control and toxicity
Ana Vasconcelos, Portugal

Symptom management

P41 Case control study; seroma control using axillary exclusion technique
Marwa Badawi, UK
P42 Case report: Fibroadenoma of the breast in identical twin
Ahmed Shalaby, UK

Triple negative breast cancer

P43 Targeting semaphorin 3C in triple negative breast cancer induces apoptosis and chemo-sensitivity
Satyam Bhasin, Canada
P44 Radiation stimulates the invasiveness and lung metastasis development in a mouse model of triple-negative breast cancer
Benoit Paquette, Canada
Skip to content